Shamburg News · 8-K filed Nov 12, 2026, 4:11 PM EST

4D Molecular Therapeutics Reports Q3 2026 Net Loss of $78.1 Million

FDMT · 4D Molecular Therapeutics, Inc.

  • Earnings
  • Materiality: high

4D Molecular Therapeutics, Inc. reported financial results for the three months ended September 30, 2026, in a press release furnished under Item 2.02. Collaboration and license revenue was $4.1 million, research and development expenses were $69.8 million, and general and administrative expenses were $15.6 million, resulting in a net loss of $78.1 million, or $1.08 per share, basic and diluted. Cash, cash equivalents and marketable securities were $375.0 million as of September 30, 2026, which the company expects to fund operations at least into the second half of 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458394.

Written from the filing by Shamburg Markets. Figures are as reported by the company.